First study drug for advanced cancers with FGFR changes
Part of Cancer clinical trials.
This early-phase study tests the safety and best dose of ABSK061 in people with advanced solid tumors. It may help people whose cancers have specific FGFR2/3 gene changes, especially urothelial cancer or cholangiocarcinoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can understand the study, and you sign consent before any study screening tests.
- You are 18 years or older and have advanced (late-stage) cancer that has worsened or can’t be treated with standard therapy.
- For the main study groups: your tumor is confirmed (by lab testing or reports) to have specific FGFR2/3 changes (fusions and/or activating mutations).
- You have at least one measurable tumor spot that doctors can track on scans, and you can get a tumor biopsy if needed.
- Your general health tests are adequate, including blood counts, liver tests, and kidney function, and you can take pills by mouth.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new drugs, ABSK061 and ABSK043, in people whose cancers have specific changes in the FGFR2 or FGFR3 genes. It may be an option if your cancer has stopped responding to standard treatments or if no standard treatment is available.
This early-phase study tests how safe ABSK-011 is, what side effects it causes, and how the body processes the drug. It may help certain patients with advanced solid cancers (including some liver cancer cases) whose tumors have specific test results.
This trial tests a new drug called ABSK211 in people with advanced solid tumors that have a change in the KRAS gene. The goal is to see if the drug is safe and works against the cancer.
This trial tests a new drug called ABSK112 for people with advanced non-small cell lung cancer, especially those whose cancer has a specific change in the EGFR gene (exon 20 insertion). The main goals are to see if it's safe and how the body handles it.
This Phase 1 study tests how safe a new drug (ABSK-021) is, what side effects it causes, and how the body processes it in people with advanced solid tumors. You may be eligible if your cancer has grown despite standard treatments or if no standard treatment exists.
This trial tests a new drug, ABSK-011, combined with standard care, against a placebo with standard care for people with advanced liver cancer that has a specific marker called FGF19 overexpression. The goal is to see if ABSK-011 can help slow the disease.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.